Amicus Therapeutics, Inc. (FOLD) Earnings Call Analysis
NASDAQ · Healthcare · Biotechnology
Earnings Reports
-
Amicus Therapeutics (FOLD) Q3 2025: Pompe Revenue Up 45% as Global Launch Accelerates
November 04, 2025
-
Amicus Therapeutics (FOLD) Q2 2025: Pombiliti and Opfolda Surge 58% as Global Launch Accelerates
July 31, 2025
-
Amicus Therapeutics (FOLD) Q1 2025: DMX-200 Deal Expands Pipeline as POMOP Guidance Cut by 20 Points
July 04, 2025